HRT and Gallbladder Disease: What the Risk Really Is, and What Changes It

HRT and gallbladder disease are linked, but a gallbladder history is not an automatic no. In randomized data, oral estrogen added about 2 to 3 gallbladder events per 1,000 women per year. Patches and gels were associated with lower risk in large observational cohorts. Active symptoms or liver disease change the answer.

That's the honest headline. Here's the part almost nobody tells you: the same gallbladder-warning sentence appeared in every one of the eight current U.S. estrogen prescribing-information records we audited — including tablets, patches, gels, and a 10-microgram vaginal insert. Word for word. What that warning can tell you, and what it cannot, is the whole rest of this page.

Best for / not for you if

This page is for you if: you have gallstones, a past gallbladder attack, or a gallbladder that's been removed, and you're deciding about HRT. It is also for you if you started or changed HRT and now have upper-right abdominal pain, or someone recommended a patch instead of a pill without explaining why.

This page is not the place to stay if: you have severe or persistent pain, fever or chills, repeated vomiting, yellow skin or eyes, dark tea-colored urine, pale stools, chest pressure, shortness of breath, or pain spreading to your jaw, back, shoulder, or arm. Get urgent medical help now.

Also not what you need if: your only question is which online HRT provider is cheapest. Start with our online HRT provider comparison instead.

Route snapshot

Route	What the evidence actually shows	What you should not conclude
Oral estrogen (pills)	The clearest causal signal. In two randomized WHI trials, oral conjugated equine estrogen regimens added about 20 to 31 gallbladder events per 10,000 women per year versus placebo.	That every pill, dose, and formulation carries the same risk. The randomized result applies to the oral regimens tested.
Transdermal estrogen (patch, gel, spray)	Two large prospective cohorts found lower gallbladder risk than with oral therapy. In the Million Women Study, relative risk was 1.17 with transdermal therapy versus 1.74 with oral therapy, compared with never-use.	That a patch is risk-free, or that a randomized trial proved it safer. No randomized gallbladder trial has directly compared the routes.
Low-dose vaginal estrogen	Systemic exposure is much lower than with systemic HRT. Direct gallbladder-outcome data specific to low-dose vaginal treatment is missing.	That systemic pill or patch numbers describe a 10-microgram vaginal insert, or that “low exposure” means “zero risk.”

What changes the answer

• Route. Tablet versus patch, gel, spray, or low-dose vaginal treatment.
• Which gallbladder situation you're actually in. Silent stones, an active attack, bile-duct disease, and a gallbladder that's already gone are different questions.
• Estrogen type and dose. In observational data, higher oral doses and oral conjugated estrogen carried more risk than lower doses and oral estradiol.
• Liver disease. Current U.S. estrogen labels treat hepatic impairment or disease as a contraindication. They treat gallbladder disease as a warning.
• Past cholestatic jaundice. That has its own label language and is not interchangeable with gallstones.
• GLP-1 treatment or rapid weight loss. These can add another gallbladder-risk signal that belongs in the same clinical conversation.
• Your state and insurance. They affect who can evaluate you, what testing can be coordinated, and what online route is actually available.

The two numbers worth remembering

Randomized WHI oral-estrogen trials: about 31 extra gallbladder events per 10,000 women per year with estrogen alone, and about 20 extra with estrogen plus progestin, compared with placebo. Million Women Study five-year cholecystectomy rates: 1.1 per 100 never-users · 1.3 per 100 transdermal users · 2.0 per 100 oral users.

Those are different studies with different designs. Do not blend them into one number. The WHI result supports a causal conclusion for the oral regimens tested. The route comparison is observational.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

---

When does gallbladder pain need care today, not another search result?

Get prompt medical care for upper-right or upper-middle abdominal pain that lasts several hours, repeated vomiting, fever or chills, yellow skin or eyes, tea-colored urine, or light-colored stools. The National Institute of Diabetes and Digestive and Kidney Diseases lists these as warning symptoms of a serious gallbladder complication. A blocked bile duct or an inflamed gallbladder can become dangerous. This page is for decisions, not for active symptoms.

One more thing, and we mean it. Heart symptoms do not always arrive as a movie-scene collapse. The American Heart Association lists chest discomfort as the most common heart-attack symptom in women, but also lists shortness of breath, nausea or vomiting, lightheadedness, and pain in the back, neck, jaw, stomach, shoulder, or arm. If you think the pain could be your heart, call emergency services. Do not use this page to sort it out.

This is not a complete list of emergency symptoms. When the symptom is severe, persistent, new, or frightening, the correct next step is medical care.

Sources: NIDDK — Symptoms & Causes of Gallstones; American Heart Association — Heart Attack Symptoms in Women.

---

HRT and gallbladder disease: is it a contraindication?

On the current U.S. estrogen labels we audited, gallbladder disease appears under Warnings and Precautions, not under Contraindications. Hepatic impairment or disease is listed as a contraindication. That does not make every gallbladder history automatically suitable for HRT; it means the condition, activity, route, and liver history must be separated instead of collapsed into one word.

We read the full Contraindications section of a current U.S. estradiol transdermal-system label. Gallstones, cholecystitis, and prior cholecystectomy are not in that list. The label places gallbladder disease in §5.4 and hepatic impairment or disease in §4.

What the current U.S. patch label puts in the “do not use” list

Listed as a contraindication	Not listed as a contraindication
Undiagnosed abnormal genital bleeding	Gallstones (cholelithiasis)
Breast cancer or a history of breast cancer	Gallbladder inflammation (cholecystitis)
Estrogen-dependent neoplasia	Prior gallbladder removal (cholecystectomy)
Active deep-vein thrombosis or pulmonary embolism, or a history of either	A stable history of biliary colic
Active arterial thromboembolic disease, such as stroke or myocardial infarction, or a history
Known anaphylactic reaction, angioedema, or hypersensitivity to the product
Hepatic impairment or disease
Protein C, protein S, or antithrombin deficiency, or another known thrombophilic disorder

Source: Estradiol Transdermal System prescribing information, DailyMed set ID c714974b-766f-42f2-a846-b0c1f5a60560, revised December 2023; record and content re-checked by The HRT Index on 6 August 2026.

That distinction matters. It does not mean a web page can clear you for treatment. It means “gallbladder disease is an absolute FDA contraindication to all HRT” is not an accurate description of the U.S. labels we checked.

Gallbladder disease, liver disease, and cholestatic jaundice are three different things

People swap these terms constantly, including in rushed clinical conversations. They are not interchangeable, and the label treats them differently.

• Gallbladder disease includes stones, inflammation, and problems involving the gallbladder or bile ducts. On the audited U.S. estrogen labels, it is a warning.
• Hepatic impairment or disease means the liver itself is impaired or diseased. On the current estradiol patch label, it is a contraindication.
• Cholestatic jaundice means bile flow has slowed or stopped enough to cause jaundice. The label says to use caution with a history linked to pregnancy or past estrogen use and to discontinue the product if cholestatic jaundice recurs.

“My gallbladder was removed” does not answer whether your liver is healthy. “My liver tests were abnormal once” does not tell you whether you have active hepatic disease. Those are separate facts a prescriber has to sort.

Current guidance does not use one universal rule

We found three current positions that belong beside each other because they answer slightly different versions of the question.

Authority	Where gallbladder disease lands	Practical reading
Current U.S. estrogen labels audited in August 2026	Gallbladder disease is under Warnings and Precautions. Hepatic impairment or disease is a contraindication.	A gallbladder history is not a class-wide automatic “no” under these labels, but it still changes risk assessment and route discussion.
Korean Society of Menopause 2025 guidelines	The guideline advises avoiding menopausal hormone therapy in active liver or gallbladder disease and takes a more conservative position than the U.S. label structure.	“Active” matters. Ongoing inflammation or obstruction is not the same situation as an incidental stone or remote surgery.
British Menopause Society HRT Guide, reviewed February 2026	Lists gall bladder disease among the indications for choosing transdermal rather than oral therapy.	It treats gallbladder history as a route-selection reason, not a universal ban.

Source: 2025 Menopausal Hormone Therapy Guidelines, Korean Society of Menopause; British Menopause Society HRT Guide, February 2026; current U.S. product labels listed in the label ledger below.

What do you do with that disagreement? Ask a better question. If someone says HRT is “contraindicated because of your gallbladder,” ask: Which source are you using, is the disease active, and are you applying that answer to every route?

The right provider for this is not the same for every woman

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

Does that sound like your situation? Get your personalized starting-point plan. Find My HRT Path takes about 90 seconds, requires no email to see your match, and separates online-care routes from situations that should start in person. Start Find My HRT Path →

---

How much does HRT actually raise gallbladder risk?

In the Women's Health Initiative, oral conjugated equine estrogen alone produced 78 gallbladder events per 10,000 person-years versus 47 with placebo. Oral conjugated equine estrogen plus medroxyprogesterone acetate produced 55 versus 35. Those differences equal about 31 and 20 extra events per 10,000 women per year.

These were two randomized, double-blind, placebo-controlled WHI trials involving 22,579 generally healthy women aged 50 to 79 without prior cholecystectomy. The paper also notes HERS as the other large randomized trial, so calling WHI the only large randomized evidence would be wrong.

The randomized numbers, by exact endpoint

“Gallbladder disease” is not one endpoint. Stones, inflammation, and surgery are different outcomes with different numbers. Mixing them is how bad statistics get born.

Outcome	Estrogen alone, HR (95% CI)	Estrogen + progestin, HR (95% CI)	What this does not prove
Any gallbladder disease or procedure	1.67 (1.35–2.06)	1.59 (1.28–1.97)	That HRT caused any one woman's symptoms or stones
Gallbladder inflammation (cholecystitis)	1.80 (1.42–2.28)	1.54 (1.22–1.94)	That a patch carries the same hazard; only oral regimens were tested
Gallstones (cholelithiasis)	1.86 (1.48–2.35)	1.68 (1.34–2.11)	That adding a progestin protects the gallbladder
Gallbladder removal (cholecystectomy)	1.93 (1.52–2.44)	1.67 (1.32–2.11)	That surgery is likely; the annual rate remained below 1%
Other biliary-tract procedures	1.18 (0.68–2.04)	1.49 (0.78–2.84)	A statistically established effect; both confidence intervals crossed 1.0

Absolute annual event rates: 78 versus 47 per 10,000 person-years with estrogen alone · 55 versus 35 per 10,000 person-years with estrogen plus progestin.

Source: Cirillo DJ, Wallace RB, Rodabough RJ, et al. “Effect of estrogen therapy on gallbladder disease.” JAMA. 2005;293(3):330–339. The HRT Index checked the endpoint definitions, hazard ratios, confidence intervals, exclusions, and absolute rates directly on 6 August 2026.

Translated into something you can actually feel

The WHI authors translated the excess rates into numbers needed to harm for one year:

• Oral estrogen alone: 31 extra events per 10,000 women per year is about one extra gallbladder event for every 323 women treated for a year.
• Oral estrogen plus progestin: 20 extra per 10,000 is about one extra event for every 500 women treated for a year.

That's the size of the thing in the trial population. Real. Not enormous. Also not zero.

How to read a number like 1.67

We're going to be blunt, because this is where a small absolute risk gets turned into a terrifying headline.

• A hazard ratio of 1.67 means the estimated hazard during follow-up was 67% higher in the treatment group than in the placebo group. It does not mean 67 out of 100 women had an event.
• Relative risk without absolute risk can make an uncommon outcome feel enormous. Read both.
• A confidence interval that crosses 1.0 means the result did not establish a statistically significant difference at the usual threshold. That is what happened for “other biliary-tract procedures.”
• Observational studies can adjust for measured differences, but unmeasured differences between people who choose patches and pills may remain.

Who the WHI gallbladder analysis did not answer for

Say this part out loud, because it changes who the headline applies to:

• Women who had already had their gallbladder removed were excluded. If that's you, these event rates were not measured in your group.
• Women with prior gallbladder disease were excluded from this analysis. The randomized result does not settle HRT decisions in women who already have stones or a history of attacks.
• The estrogen tested was oral conjugated equine estrogen, alone or with medroxyprogesterone acetate — not a patch, gel, spray, or low-dose vaginal insert.
• The authors explicitly said the findings could not necessarily be extrapolated to other estrogen types or routes.

Why numbers online often do not match

While checking this page against the original paper, we found three recurring errors worth protecting you from:

• The cholecystitis and cholecystectomy hazard ratios are sometimes swapped. The estrogen-alone values are 1.80 for cholecystitis and 1.93 for cholecystectomy.
• The total treatment-arm rates — 78 and 55 per 10,000 person-years — are sometimes called “extra” events. The actual excesses over placebo are 31 and 20.
• A hazard ratio is sometimes called an odds ratio. It is not. The WHI analysis used Cox proportional-hazards models.

We're not naming pages. We're giving you the source so you can check us the same way we checked them.

---

Are estrogen patches safer for your gallbladder than pills?

Two large prospective cohorts found substantially lower gallbladder risk with transdermal estrogen than with oral estrogen. A later South Korean claims study reported the opposite pattern, and its authors flagged selection bias as a possible explanation. No randomized trial has directly compared a patch with a pill for gallbladder outcomes.

That makes “lower observed risk” the accurate phrase. “Proven safer” is too strong.

The route evidence in one table

Study	Design and size	What it found on route	What it does not prove
Million Women Study — BMJ 2008;337:a386	Prospective cohort of 1,001,391 women; 19,889 gallbladder admissions, most followed by cholecystectomy	Current use RR 1.64 overall. Transdermal RR 1.17 versus oral RR 1.74, each compared with never-use. Five-year cholecystectomy rates: 1.3 per 100 transdermal users versus 2.0 per 100 oral users and 1.1 per 100 never-users.	Cause and effect. Route was not randomized.
E3N cohort — CMAJ 2013;185:555–561	Prospective cohort of 70,928 French women; mean follow-up 11.5 years; 2,819 cholecystectomies	Overall menopausal hormone therapy HR 1.10. The increase was chiefly associated with unopposed oral estrogen (HR 1.38). Transdermal estrogen was not associated with increased cholecystectomy risk in the cohort.	That transdermal therapy prevents gallbladder disease or carries no risk.
South Korean national claims cohort — PLOS ONE 2023;18:e0294356	Retrospective claims cohort; 1,004,034 non-users and 381,711 MHT users	Every analyzed MHT group showed increased gallstone hazard. The database's “topical estrogen” category had the highest adjusted HR, 1.602; oral estrogen alone was 1.241.	A product-specific result for an estradiol patch, gel, or low-dose vaginal insert. The category was broad, and the authors identified possible selection bias.

Source: Million Women Study, BMJ; E3N cohort, CMAJ/PMC; South Korean claims cohort, PLOS ONE.

The Million Women Study authors estimated that using transdermal rather than oral therapy for five years would avoid about one cholecystectomy per 140 users, based on their standardized observational rates. That is useful scale. It is not a promise and it was not produced by a randomized route trial.

Here's the part we could have left out

We're going to tell you something that weakens the clean “choose a patch” answer, because you deserve to hear it here instead of discovering it after you've made a decision.

The strong evidence is that the oral WHI regimens increased gallbladder events. The transdermal advantage comes from observational cohorts and a plausible mechanism. No trial has randomly assigned women to a patch or a pill and then counted gallbladder outcomes.

The studies also do not make a patch friction-free. Patches can cause skin irritation, loosen or detach, and may not match every woman's symptom pattern, preference, insurance formulary, or prior response. Gels and sprays have their own application and transfer considerations. A route can be a better risk fit and still be a worse practical fit.

So why is route still the right question to ask? Because the two largest prospective cohorts pointed in the same direction, the British Menopause Society lists gallbladder disease as a reason to prefer transdermal therapy, and avoiding the initial oral first-pass exposure is biologically relevant. That earns a route conversation. It does not earn a guarantee.

If you have active symptomatic gallbladder disease, a bile-duct stone, unresolved jaundice, pancreatitis, or surgery already scheduled, this is not primarily a patch-versus-pill decision. Settle the biliary problem first.

If route is the decision in front of you, sort it before the appointment starts. Find My HRT Path maps symptoms, uterus status, route preference, risk history, insurance, and state to the online-care models that fit — and flags when an in-person start makes more sense. Check what fits your situation →

---

Why does my patch leaflet warn about gallbladder disease?

Because the same non-route-specific gallbladder sentence appears across estrogen prescribing information. In the eight current U.S. records we audited, the warning appeared on an oral estradiol tablet, three transdermal patches, three estradiol gels, and Vagifem 10 micrograms. The sentence tells you about an estrogen-class association; it does not quantify your product-specific risk.

This is one of the most useful findings on the page because the warning can look as though it came from a trial of the exact product in your hand. Often it did not.

The eight-label ledger

Product record and route	Gallbladder warning found?	Exact finding	Source checked 6 Aug 2026
Estradiol tablet — oral	Yes	Same “2- to 4-fold” class sentence	DailyMed set ID ecfe8bfd-f6f3-4fed-b881-b6ea140231b8
Estradiol transdermal system — patch	Yes, §5.4	Same sentence; no route-specific estimate	DailyMed set ID c714974b-766f-42f2-a846-b0c1f5a60560
Estradiol transdermal system — patch	Yes	Same sentence	DailyMed set ID bf185599-2138-4083-9c52-2b95dce09ae0
Estradiol transdermal system — patch	Yes	Same sentence	DailyMed set ID 839fe7ae-6835-4d6a-b6b1-ca7f062caa4f
Estradiol gel — transdermal	Yes	Same sentence	DailyMed set ID 9669a0e3-27e2-4f6c-961c-7a67e9f84cc8
Estradiol gel — transdermal	Yes	Same sentence	DailyMed set ID 3ac905b3-904c-4285-97ed-e787d006c7dd
Estradiol gel — transdermal	Yes	Same sentence	DailyMed set ID 1a46efe6-21b9-3f0f-90b9-59f279ef51df
Vagifem 10 mcg — vaginal insert	Yes, §5.5 in the current record	Same sentence	DailyMed set ID e5ad3cf6-dd96-4e64-af21-c1eee38d0b88

The sentence, quoted once:

“A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.”

On the patch label we examined most closely, that one sentence is the entire Gallbladder Disease subsection. It gives no route-specific absolute rate, dose estimate, or trial population.

The same patch label explains why route still matters

The pharmacokinetics section of that patch label says systemic availability of estradiol after transdermal administration is about 20 times higher than after oral administration because the transdermal route avoids initial first-pass metabolism.

That sentence is easy to misuse. It does not mean a standard patch produces 20 times the blood level of a prescribed oral dose. It is a relative-bioavailability statement about how much administered estradiol reaches systemic circulation. Patch and tablet milligram amounts are not interchangeable, and this is not a dosing calculator.

The clinically relevant point is smaller and cleaner: oral estradiol goes through the gut and reaches the liver before the general circulation, while transdermal estradiol avoids that initial concentrated first pass.

The WHI gallbladder paper makes the evidence boundary explicit: its findings could not necessarily be extrapolated to other estrogen types or routes, and transdermal gallbladder outcomes needed further study.

So one evidence set gives you all three truths at once:

1. Current estrogen labels can carry the same class warning across routes.
2. Oral and transdermal delivery have different pharmacokinetics.
3. The randomized gallbladder result came from oral conjugated equine estrogen regimens, not from a direct patch-versus-pill trial.

What this does not mean: that the label is wrong, that a patch has no gallbladder risk, or that you can ignore symptoms.

What it does mean: the leaflet's class sentence is not a personalized estimate for your route, dose, gallbladder history, or current symptoms. The studies and your clinical history do that work.

Why your leaflet may not match someone else's in 2026

FDA menopause-hormone labeling is in a staged update. On 12 February 2026, the FDA announced approval of labeling changes for an initial six menopausal hormone products after 29 companies submitted proposed changes. The rollout is product-specific, so two current leaflets can differ while updates move through separate applications.

That is why this ledger identifies the exact DailyMed record and verification date instead of saying “the estrogen label” as though only one exists.

Source: FDA — Labeling Changes to Menopausal Hormone Therapy Products, 12 February 2026.

---

Does low-dose vaginal estrogen carry the same gallbladder risk?

Nobody has produced a direct gallbladder-outcome estimate for low-dose vaginal estrogen. Systemic exposure is much lower than with systemic HRT, so importing oral WHI event rates would be scientifically wrong. But “much lower exposure” is not the same claim as “zero gallbladder risk,” and Vagifem 10 micrograms still carries the class warning.

This section matters if your symptoms are mainly vaginal dryness, painful sex, burning, urinary urgency, or recurrent urinary symptoms — the cluster called genitourinary syndrome of menopause, or GSM.

The Menopause Society describes low-dose vaginal estrogen as a local treatment with very little entering the bloodstream. That makes it a fundamentally different exposure decision from taking systemic estrogen for hot flashes, night sweats, or whole-body symptom control.

Two things we will not do here:

• We will not tell you low-dose vaginal estrogen has zero gallbladder risk. Direct outcome data does not support that sentence.
• We will not use oral or transdermal gallbladder numbers to imply a precise risk for a vaginal insert, tablet, ring, or cream. Those are different exposures and different questions.

What we will say: if your symptoms are local, ask whether a local treatment can meet the treatment goal without exposing you to a systemic regimen you do not need. That is not a promise that local therapy is risk-free. It is a way to make the treatment match the symptom.

One terminology trap deserves its own warning. The South Korean claims study used a database category called “topical estrogen.” The paper does not turn that category into a product-specific result for Vagifem 10 micrograms or every low-dose vaginal product. Do not let a search summary silently convert “topical” into “low-dose vaginal” and hand you a false level of precision.

Sources: The Menopause Society — Hormone Therapy; Vagifem prescribing information.

---

Which gallbladder situation are you actually in?

“Gallbladder disease” covers several clinically different situations. An incidental stone is not the same as active cholecystitis, a bile-duct stone, pancreatitis, or a remote cholecystectomy. The strongest randomized HRT data excluded women with prior gallbladder disease and prior cholecystectomy, so your category matters before anyone quotes you a trial number.

Find yourself in the table, then read the detail beneath it.

Your situation	What it generally means	What the HRT evidence can say	Where to start
Silent stones — found incidentally, no symptoms	Many gallstones never cause symptoms; asymptomatic stones often do not need gallstone treatment	Thin. WHI excluded women with known gallbladder disease	Prescriber route discussion, with imaging and liver history available
Past biliary-colic attack, now resolved	A stone has caused symptoms before, even if the episode ended	Thin for women with pre-existing disease	Prescriber or primary-care review; specialist input if attacks recur
Active or recurrent cholecystitis	Ongoing or repeated inflammation, often with persistent pain or systemic symptoms	Not a routine online-HRT decision; conservative guidance advises avoiding MHT in active gallbladder disease	In-person evaluation, gastroenterology, or surgery first
Bile-duct stone, prior ERCP, gallstone pancreatitis, or persistent jaundice	More complicated biliary disease with possible duct or pancreatic involvement	Not directly resolved by HRT route studies	Specialist first, then HRT sequencing
Gallbladder already removed	The organ is gone, but bile ducts, liver history, and post-surgical symptoms still matter	Very thin; WHI excluded prior cholecystectomy	Prescriber review with the reason for surgery and any remaining duct/liver issues documented

Can you take HRT with silent gallstones?

You are in one of the largest and least-studied groups. NIDDK says gallstones that do not cause symptoms generally do not need treatment. That answers the stone-treatment question. It does not automatically answer the HRT question.

The randomized WHI gallbladder analysis excluded women with known gallbladder disease. So the honest position is neither automatic eligibility nor automatic exclusion.

Bring these questions:

• Was the stone truly incidental, or was the scan ordered because of symptoms?
• Did the report mention the common bile duct, sludge, wall thickening, or inflammation?
• Are bilirubin and liver-test results normal?
• Does my history make a transdermal route more sensible than an oral one?
• What symptoms should trigger a call or urgent assessment?

Things we will not tell you because the data does not support them: that silent stones make HRT “safe,” that a patch prevents an attack, or that no follow-up is needed.

What if you're having active attacks or inflammation?

This one is simpler and more important. Get the gallbladder problem assessed and settled first. Active or recurrent pain, inflammation, obstruction, jaundice, or pancreatitis needs diagnostic work that an HRT comparison page cannot provide.

It is not necessarily a permanent no on HRT. It is an order of operations.

Can you take HRT after gallbladder removal?

Prior cholecystectomy is not listed as a contraindication on the U.S. estrogen labels we audited. The headline WHI event rates were never measured in this group because women with prior cholecystectomy were excluded.

After removal, bile no longer collects in the gallbladder before being released. Most people do well, but bile-duct stones and post-cholecystectomy digestive symptoms can still occur. The reason for surgery also matters: uncomplicated stones are not the same history as bile-duct obstruction, pancreatitis, cholangitis, or persistent abnormal liver tests.

What does not disappear after surgery is the rest of the route question. Oral estrogen still has an initial hepatic first pass. Transdermal therapy still avoids it. That makes route worth discussing even when there is no gallbladder left — just not on the basis of a post-cholecystectomy trial, because we could not find one that gives a useful patient-level answer.

Here is what we could not find, and we looked hard: a randomized or strong prospective study measuring HRT gallbladder or biliary outcomes specifically in women after cholecystectomy. If a page declares HRT definitively safe or definitively unsafe after removal, ask where that direct evidence is.

For more context on menopause after ovary or uterine surgery, see What Is Surgical Menopause?.

What if you've had cholestatic jaundice or have liver disease?

Different category. This is where the label becomes restrictive.

If you had cholestatic jaundice during pregnancy or with past estrogen use, the audited patch label directs caution and says to discontinue treatment if cholestatic jaundice recurs.

If you have hepatic impairment or disease, the current patch label lists that as a contraindication. That is a liver answer, not a gallbladder answer, and it needs a clinician who can interpret the diagnosis and current function.

---

Does progesterone matter, or is this just about estrogen?

Estrogen has the strongest causal evidence, while progesterone and progestins may also affect gallbladder emptying. In WHI, gallbladder events increased in both the estrogen-alone and estrogen-plus-progestin trials. Those trials used different populations, so their absolute rates cannot prove that adding progestin lowers or raises an individual woman's gallbladder risk.

The WHI treatment-arm rates were 78 per 10,000 person-years with estrogen alone and 55 per 10,000 with estrogen plus progestin. Those are total rates, not excess rates. The excesses versus each trial's placebo group were 31 and 20.

The French E3N cohort complicates the easy “progestogen is the villain” story. Its strongest cholecystectomy signal appeared with unopposed oral estrogen, not with a progestogen-containing regimen.

Here is the line that matters more than the mechanism: if you have a uterus and use systemic estrogen, do not stop or skip the endometrial-protection plan prescribed for you because of this page. Protection may involve a progestogen, a suitable 52 mg levonorgestrel intrauterine system, or another clinician-selected regimen. If the protective component is causing problems, ask about the option and route. Do not silently remove it.

---

How does estrogen affect the gallbladder?

Estrogen can increase cholesterol secretion into bile, making bile more prone to cholesterol-crystal and stone formation. Progesterone or progestins may reduce gallbladder motility. These mechanisms make the epidemiologic association plausible, but they cannot prove that HRT caused a specific stone, diagnose abdominal pain, or choose a prescription for you.

Three steps, plain language:

1. Bile becomes more saturated with cholesterol. Past a point, cholesterol can come out of solution and begin forming crystals.
2. Crystals can grow into stones. This often happens slowly and silently.
3. Slower or less complete gallbladder emptying can leave bile sitting longer. Concentrated, stagnant bile is more likely to form stones.

Why the route plausibly changes this

Swallow a pill and it moves through the gut, then reaches the liver through the portal circulation before entering the general circulation. That is the initial first-pass exposure.

Apply estradiol through the skin and it enters the general circulation without that initial concentrated pass through the gut and liver. Because the liver makes bile and regulates many proteins and lipids, that route difference is relevant.

One correction worth keeping because the wrong version is everywhere: a patch does not “bypass the liver.” Everything circulating in your blood eventually reaches the liver. A patch avoids the initial first-pass metabolism that follows an oral dose. That is the accurate claim.

What mechanism cannot do: tell you whether HRT caused your stone, tell you whether a patch is right for you, or replace an examination, liver tests, or ultrasound.

---

What if you're also on a GLP-1 or losing weight quickly?

Then your clinician needs the whole medication and weight-change picture, not two separate half-histories. Current FDA labeling for semaglutide and tirzepatide reports gallbladder events, and rapid or substantial weight loss is itself a recognized risk factor for gallstones. These figures come from different trials and cannot be added together or ranked head-to-head.

Nobody handed midlife women one clean table, so we assembled the current labeled rates beside their own control groups.

Exposure	Gallbladder finding in the source	Control group in the same source	What the number can and cannot do
Oral conjugated equine estrogen alone in WHI	Any gallbladder event: 78 per 10,000 person-years	47 per 10,000 person-years with placebo	Supports a causal increase for the oral regimen tested; does not predict your personal risk
Oral conjugated equine estrogen + medroxyprogesterone acetate in WHI	55 per 10,000 person-years	35 per 10,000 person-years with placebo	Same limit: randomized evidence for that regimen, not every modern HRT product
Wegovy injection in adult weight-reduction trials	Cholelithiasis 1.6%; cholecystitis 0.6%	0.7%; 0.2% with placebo	Product-label trial rates; not directly comparable with WHI or Zepbound trials
Wegovy tablet in the current label	Cholelithiasis 2.5%	1.0% with placebo	Different formulation and trial program; not a route ranking against the injection
Zepbound in pooled weight-reduction trials	Cholelithiasis 1.1%; cholecystitis 0.7%; cholecystectomy 0.2%	1.0%; 0.2%; 0% with placebo	Product-label rates in its own trials; not evidence that it is safer or riskier than semaglutide
Rapid or substantial weight loss	Recognized gallstone risk factor; Wegovy labeling says the excess acute gallbladder disease remained greater than placebo even after accounting for weight loss	—	A reason to discuss pace, symptoms, and medication history — not a reason to stop treatment on your own

Source: Wegovy prescribing information, FDA, 2026; Zepbound prescribing information, FDA, 2026; NIDDK — Dieting & Gallstones; WHI gallbladder analysis.

Read the table the right way. It is not a cross-drug leaderboard. The populations, durations, event definitions, and reporting systems differ.

It exists for one purpose: bring HRT, GLP-1 treatment, the pace of weight change, prior stones, and current symptoms into one appointment. The common failure mode is an HRT prescriber seeing only the hormones while a weight-management prescriber sees only the GLP-1.

---

Is this pain your gallbladder — or something else?

Gallbladder pain often sits in the upper-right or upper-middle abdomen, may follow a meal, can spread toward the right shoulder or back, and may last from minutes to several hours. But reflux, pancreatic disease, medication irritation, and cardiac symptoms can overlap. A pattern can help you describe the pain; it cannot safely diagnose it.

What you're noticing	What it may fit	What raises urgency	Best next step
Upper-right or upper-middle pain, sometimes after food, possibly spreading toward the right shoulder or back	Gallstone-related pain is one possibility	Pain lasting hours, fever, jaundice, repeated vomiting, dark urine, pale stool	Prompt in-person assessment; emergency care with red flags
Burning behind the breastbone, acid taste, worse lying down	Reflux is one possibility	Trouble swallowing, vomiting blood, black stool, severe chest pain	Medical assessment; see Menopause and Acid Reflux for the non-emergency overlap
Chest pressure or discomfort, shortness of breath, nausea, lightheadedness, jaw/back/shoulder/arm pain	Possible cardiac symptoms	The pattern itself is urgent when new or concerning	Call emergency services
Severe persistent upper-abdominal pain that may go through to the back, especially with vomiting	Possible pancreatitis or another acute abdominal problem	Persistent severe pain or inability to keep fluids down	Emergency care
Nausea without a clear pattern after starting or changing medication	Medication effect or another gastrointestinal cause is possible	Dehydration, severe pain, blood, jaundice, or persistent vomiting	Contact the prescriber; see Menopause and Nausea for broader causes

Build a timeline instead of a theory

If the pain began after you started or changed HRT, document the sequence:

• Exact product, dose, and route
• Start date and any dose-change date
• Where the pain is and where it travels
• How long it lasts
• Whether meals seem related
• Nausea, vomiting, fever, chills, jaundice, urine color, and stool color
• Previous stones, attacks, ERCP, pancreatitis, surgery, or liver problems
• Dates and results of imaging or laboratory tests
• GLP-1 treatment and recent weight change

That record is more useful in an appointment than a theory you cannot test safely.

One thing not to do

Do not stop and restart HRT on your own to “prove” it caused the pain. You cannot blind the experiment or control for meals, stones, infection, medication changes, and normal symptom variation. You may lose symptom control while delaying the workup that could identify the real problem.

A clinician may decide that a pause is appropriate. That is a plan. Rechallenging yourself is not.

---

If I stop HRT, does the gallbladder risk go away?

The Million Women Study found that gallbladder risk declined with time after hormone therapy stopped, but past users still had a statistically detectable excess more than ten years later. That observational finding does not show that stopping today immediately removes risk, and it does not tell an individual woman whether stopping is the right tradeoff.

That's an uncomfortable result, and we'd rather you hear it than not.

What it supports: route deserves attention at the beginning, before habit and symptom control make a change harder.

What it does not support: stopping abruptly in panic. A stop decision has to weigh why you use HRT, what symptoms may return, the exact product and route, and the rest of your health history. The gallbladder study does not contain that entire benefit-risk decision.

If you want to stop, that is a legitimate choice. Make it with the prescriber and a plan for what happens next.

Source: Million Women Study, BMJ.

---

What should you bring and ask before an HRT decision?

Bring the record that lets a clinician distinguish an incidental stone from active disease and a past cholecystectomy from unresolved bile-duct or liver problems. Then ask the route question directly. Do not assume the gallbladder history will come up unless you put it on the table.

Bring, if you have them

• Ultrasound, CT, MRI, HIDA, or other imaging reports, with dates
• Operative report or discharge summary from gallbladder surgery
• ERCP or pancreatitis records
• Liver tests and bilirubin results
• A timeline of attacks and current symptoms
• The exact name, dose, and route of every HRT product you've used
• Your complete medication list, including GLP-1 treatment
• Recent weight change and how quickly it happened

Say these questions out loud

1. “Given my gallbladder history, is there a reason to prefer transdermal estrogen over oral estrogen for me?”
2. “Which part of my history changes the decision: the stone, active symptoms, bile-duct history, liver results, or something else?”
3. “If we use an oral product, what symptom or result would make us reconsider the route?”
4. “Do my bilirubin or liver-test results need to be repeated or interpreted before we decide?”
5. “Does my surgery, ERCP, pancreatitis, or bile-duct history need specialist input?”
6. “If my symptoms are mainly vaginal or urinary, could a low-dose local treatment meet the goal?”
7. “If upper-right pain returns, who do I call and what symptoms mean urgent care?”
8. “If you are not comfortable prescribing, which specific factor is driving that decision?”

Do not accept these as a complete evaluation

• “Estrogen is estrogen.” Route, formulation, dose, and exposure differ.
• “Gallstones mean no HRT,” with no discussion of whether the stones are silent, symptomatic, active, or already surgically treated.
• “A patch has no gallbladder risk.” The observational evidence is lower-risk, not zero-risk.
• “The leaflet proves your patch has a two- to four-fold personal risk.” The sentence is a class warning, not a product-specific individual estimate.
• New upper-right pain being waved off as “just hormones” without considering examination, labs, or imaging.
• Being told to stop HRT for abdominal pain without anyone deciding how the pain itself will be evaluated.

Walk into the appointment with the route question already framed. Find My HRT Path gives you a private starting-point match based on symptoms, risk history, preferred route, insurance, state, and whether online care is an appropriate first stop. Build your HRT starting-point plan →

---

When is online HRT care the wrong place to start?

Online menopause care can fit a stable, already evaluated gallbladder history when the clinician can review records and coordinate local testing. It is the wrong first stop for active biliary symptoms, unresolved inflammation, jaundice, possible bile-duct obstruction, pancreatitis, active liver disease, or severe undiagnosed abdominal pain.

Start in person first if

• You have any urgent symptom listed near the top of this page
• Pain is severe, persistent, recurrent, or has not been diagnosed
• You have fever, jaundice, dark urine, pale stool, or repeated vomiting
• You have unresolved or recurrent cholecystitis
• You have a known bile-duct stone, recent ERCP, cholangitis, or gallstone pancreatitis
• Liver or bilirubin results are abnormal and unexplained
• You have known active liver disease
• You recently had surgery and symptoms are ongoing
• You need an abdominal examination or same-day imaging

Online care may be a reasonable entry point when

• You have no urgent symptoms
• The gallbladder history is stable and already worked up
• You can share imaging, surgical, and laboratory records
• The service can coordinate or order local testing when needed
• You understand that a consultation does not guarantee a prescription
• Your real decision is route, formulation, symptom fit, or ongoing HRT management

A video visit can take a history and review records. It cannot palpate your abdomen, perform an ultrasound, or substitute for emergency care.

---

Where does online menopause care fit in this decision?

If the unresolved question is which HRT route fits a stable, documented history, a menopause-focused online clinician may be useful. If the unresolved question is what is causing current abdominal pain, start with a clinician who can examine you and arrange prompt diagnostic testing. The provider choice follows that split.

We may earn a commission if you start care through some links below, at no extra cost to you. Commercial relationships do not change the facts we verify or the readers we tell to start elsewhere. See our affiliate disclosure for details.

Provider-stated vs verified — checked 6 August 2026

Provider	Where it fits on this page	Price and coverage verified	Testing and access verified	Cancellation / material limitation verified
Midi Health	A menopause-focused route and medication-history discussion when your gallbladder problem is stable and already evaluated	Self-pay: $250 initial visit; $150 continued-care visit. In-network with most PPO plans; exact coverage and out-of-pocket cost vary by plan. Available in all 50 states.	Midi says clinicians can order bloodwork or imaging and direct patients to local facilities. It cannot perform an abdominal exam or imaging during a virtual visit.	Midi advises changing or cancelling a visit at least 24 hours ahead to avoid a cancellation fee; the exact fee was not published on the page we verified. Medicaid/Medi-Cal patients cannot be treated, even self-pay. Medicare beneficiaries may use self-pay but cannot submit related claims.
Sesame	A cash-pay marketplace that may help you search for a local in-person or video appointment when you need broader primary, gynecology, or specialist access	Price is displayed before booking and varies by clinician, service, and ZIP. $34 applies to virtual urgent care offers, not to every menopause, gynecology, or in-person visit. Sesame does not accept insurance.	In-person options depend on local provider availability. Sesame is a marketplace; the listed clinician supplies the care. Virtual urgent care is not appropriate for emergencies or conditions requiring hands-on examination or in-person imaging.	Full-refund window in current terms: virtual visit cancelled at least 3 hours ahead; in-person visit at least 24 hours ahead; other undated services follow the terms' 10-day rule if not used. Terms require users to certify they are not Medicare, Medicaid, or TRICARE beneficiaries.

Source: Midi pricing and insurance; Midi how it works; Midi cancellation guidance; Sesame Terms of Service; Sesame virtual urgent care; Sesame telehealth marketplace.

Midi Health — strongest fit for a stable route conversation

Midi's advantage here is not that it can diagnose an acute gallbladder problem through a screen. It cannot. The fit is a different one: it offers menopause-focused virtual visits, operates in all 50 states, works with most PPO plans, and says its clinicians can review the full history and order local bloodwork or imaging when needed.

The cash-pay price is $250 for the initial visit and $150 for continued-care visits. With insurance, the actual patient responsibility depends on the exact plan, deductible, copay, and coinsurance. Do not use a national average to guess your bill; confirm your plan before booking.

Midi publishes FDA-approved hormonal prescription options. It also operates Custom Rx pages for compounded estradiol products. Those are separate categories. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing. If your priority is an FDA-approved estradiol patch, gel, tablet, ring, insert, or cream, say that plainly and verify the exact product before paying.

Now the honest limitation, and it is a real one. Midi cannot perform the physical examination or imaging that severe or undiagnosed abdominal pain may need. It can coordinate testing, but that is not the same as being examined today. If pain is the question, in-person care comes first. If route is the question and the biliary history is stable, Midi is the cleaner fit.

Who should not go here: Medicaid and Medi-Cal patients cannot be treated, even as self-pay. Medicare beneficiaries can use self-pay, but Midi is not covered by Medicare and related claims cannot be submitted. Anyone with urgent symptoms should bypass booking and seek urgent or emergency care.

If your history is stable and the remaining question is route, check your exact plan and state access before booking. See Midi's current coverage and self-pay pricing →

Sesame — useful when you need a local appointment search, not an HRT program

Sesame is not a dedicated menopause program. It is a cash-pay marketplace where independent clinicians list video and in-person services at prices shown before booking. That can be useful when you need to search for a local primary-care, gynecology, or other appointment rather than enter a recurring HRT program.

Do not carry the $34 headline into every search. The verified $34 figure is attached to virtual urgent care offers. A menopause, gynecology, specialist, or in-person appointment can cost more, and the exact price appears with the provider listing.

The limitation is sharp: availability depends on your ZIP and the independent clinicians listed there. Sesame does not accept insurance, and its current terms require users to certify that they are not Medicare, Medicaid, or TRICARE beneficiaries. It is not an emergency route and it cannot make a video visit perform an ultrasound.

If you need to search local cash-pay options, see the actual clinician, format, time, and price before you book. Check Sesame availability in your area →

Who we deliberately left off this page

You are owed the reasoning, not just two names.

• Compounded-primary HRT programs are not featured as the answer to this route question. This page depends on FDA-approved product labels and route-specific pharmacokinetics. A compounded transdermal cream is not interchangeable with an FDA-approved patch, and there is no reliable evidence that compounded hormone therapy is safer for the gallbladder.
• Providers without a current public state-availability path or clear price structure are not featured. We cannot verify fit for the reader.
• Vaginal-only compounded products are not used to answer a systemic patch-versus-pill question.
• General urgent-care telehealth is not positioned as the answer to red-flag abdominal symptoms. The need for examination or imaging overrides affiliate conversion.

The FDA's position is direct: compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing. Compounding can meet legitimate patient needs when an approved product is not medically appropriate, but it is not a route around evidence, labeling, or evaluation.

Source: FDA — Compounding and the FDA: Questions and Answers.

That's how The HRT Index Verification Standard works: we read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule — top providers monthly, the full roster quarterly. We evaluate providers on five things, in this order: clinical legitimacy, care quality, medication fit, price transparency, access. No invented scores. No stars. Just what we checked and when.

---

What did The HRT Index actually verify for this page?

We checked the primary trial tables, current prescribing information, guideline language, FDA GLP-1 labels, and live provider terms instead of relying on summaries. We also preserved the missing answers: no randomized patch-versus-pill gallbladder trial, no direct low-dose vaginal gallbladder rate, and no useful outcome study specifically after cholecystectomy.

Verified directly on 6 August 2026

1. Eight current U.S. estrogen prescribing-information records across oral, patch, gel, and vaginal routes, checked for gallbladder warning language, contraindications, hepatic impairment, cholestatic jaundice, and pharmacokinetics.
2. The WHI gallbladder analysis in JAMA, including trial design, exclusions, exact endpoints, hazard ratios, confidence intervals, annual event rates, excess rates, and the authors' route limitation.
3. The Million Women Study, including oral versus transdermal relative risks, standardized five-year cholecystectomy rates, dose and formulation differences, the one-per-140 estimate, and risk after stopping.
4. The French E3N cohort, including cohort size, follow-up, overall risk, unopposed oral-estrogen finding, and transdermal result.
5. The South Korean national claims cohort, including the “topical estrogen” counter-finding, exact adjusted hazard ratios, gallbladder-cancer result, and the authors' selection-bias warning.
6. The 2025 Korean Society of Menopause guidelines and February 2026 British Menopause Society HRT Guide for the disagreement over active disease and transdermal route selection.
7. Current FDA Wegovy and Zepbound prescribing information for gallbladder event rates and placebo comparisons.
8. Midi and Sesame primary pages and terms for price, coverage, federal-program restrictions, state access, testing, booking, and cancellation details.
9. The HRT Index's live Find My HRT Path page for the approximately 90-second timing and no-email-before-results claim.

What we are not claiming

• A personal gallbladder-risk percentage for any individual
• That transdermal estrogen or low-dose vaginal estrogen has zero gallbladder risk
• That HRT caused any specific woman's stone, attack, or surgery
• A randomized answer for women who already have gallbladder disease
• A randomized answer for women after gallbladder removal
• That the label's “2- to 4-fold” sentence is a product-specific risk estimate for every route carrying it
• That an online visit can replace an examination, ultrasound, emergency assessment, or specialist decision
• That a consultation guarantees an HRT prescription
• Medical review by a clinician; this page has not had one

Refresh plan

Element that can go stale	Re-check cadence	Verification method
U.S. estrogen labels and warning sections	Quarterly during the current FDA relabeling rollout	Open each exact DailyMed set ID and FDA label record
New route or post-cholecystectomy evidence	Quarterly	Standing PubMed and journal search; read full primary paper before changing claims
Menopause-society guidance	Every six months, or on publication of an update	Check the issuing society's current guideline or clinician guide
Wegovy and Zepbound event rates	Quarterly	Check the latest FDA-approved prescribing information
Midi price, insurance, state access, testing, and restrictions	Monthly	Verify live pricing, insurance, how-it-works, and terms pages
Sesame pricing, availability, federal-program restrictions, and cancellation terms	Monthly	Verify live listings and current Terms of Service
Find My HRT Path timing and privacy claims	With every tool release	Test the live tool and compare visible copy with actual behavior

The “Last verified” date changes only after these checks are actually repeated.

---

Frequently asked questions

Can HRT cause gallstones?

Systemic oral estrogen can increase gallstone and gallbladder-event risk. In the randomized WHI trials, oral conjugated equine estrogen regimens produced about 20 to 31 extra gallbladder events per 10,000 women per year versus placebo. That supports a causal increase for the regimens tested; it does not prove HRT caused one person's stone.

Is a patch safer than a pill for my gallbladder?

Large observational cohorts found lower gallbladder risk with patches and gels than with pills. In the Million Women Study, relative risk was 1.17 with transdermal therapy versus 1.74 with oral therapy, compared with never-use. No randomized gallbladder trial has directly compared the routes, so “lower observed risk” is more accurate than “proven safe.”

Is gallbladder disease a contraindication to HRT?

Not under the current U.S. estrogen-label structure we audited: gallbladder disease appears under Warnings and Precautions, while hepatic impairment or disease appears under Contraindications. Some international guidance is more conservative for active gallbladder disease, and the British Menopause Society lists gallbladder disease as a reason to favor transdermal therapy.

Can I take HRT after my gallbladder was removed?

Prior cholecystectomy is not listed as a contraindication on the U.S. labels we reviewed. Direct outcome evidence is limited because the WHI gallbladder analysis excluded women with prior cholecystectomy. A clinician should review why surgery was needed and whether bile-duct, pancreatic, liver, or ongoing digestive issues remain.

Can I take HRT if I have silent gallstones?

Silent stones usually do not need gallstone treatment, but that does not settle HRT candidacy. The major randomized analysis excluded women with known gallbladder disease. Ask about current symptoms, bile-duct and liver history, route, and what follow-up would be needed.

Does low-dose vaginal estrogen affect the gallbladder?

No direct study has produced a gallbladder-outcome rate specific to low-dose vaginal estrogen. Systemic exposure is much lower than with systemic HRT, so oral WHI rates should not be imported. Vagifem 10 micrograms still carries the class gallbladder warning, and “low exposure” should not be rewritten as “zero risk.”

Does progesterone cause gallbladder problems?

Progestogens may reduce gallbladder motility, but the strongest causal evidence centers on oral estrogen regimens. WHI found increased gallbladder events in both estrogen-alone and estrogen-plus-progestin trials, and E3N's strongest signal appeared with unopposed oral estrogen. Do not stop prescribed endometrial protection based on this page.

Should I stop HRT if I have a gallbladder attack?

Do not decide from a web page or run your own stop-restart experiment. Contact the prescriber and get prompt medical care for pain lasting hours, repeated vomiting, fever or chills, jaundice, dark urine, or pale stools. Severe or concerning symptoms belong in urgent or emergency care.

Does the risk disappear when I stop HRT?

The Million Women Study found risk declined over time after stopping, but past users still had a measurable excess more than ten years later. That observational finding supports thinking about route before starting; it does not tell you to stop abruptly or calculate how quickly your personal risk will change.

Does the estrogen dose matter?

In the Million Women Study, higher oral doses were associated with higher gallbladder risk. Higher-dose oral conjugated estrogen had a relative risk of 1.91 versus 1.76 at lower dose; higher-dose oral estradiol had a relative risk of 1.68 versus 1.44. These are observational comparisons, not individualized dose instructions.

Does the type of oral estrogen matter?

In the Million Women Study, oral conjugated equine estrogen carried a slightly higher relative risk than oral estradiol: 1.79 versus 1.62, each compared with never-use. That does not make either oral option risk-free, and it does not substitute for a route discussion.

Can HRT cause gallbladder cancer?

The established concern here is gallstones, inflammation, and surgery. The South Korean national claims study did not find a statistically significant increase in gallbladder cancer across its hormone-therapy groups. That is reassuring within that study, not a lifetime guarantee.

Is compounded HRT safer for the gallbladder?

No reliable evidence establishes that. Compounded products are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing. A compounded cream is not interchangeable with an FDA-approved patch for interpreting product labels or route-specific pharmacokinetics.

What is the difference between gallbladder disease and liver disease?

The liver makes bile and performs metabolic work; the gallbladder stores bile. On the current U.S. estradiol patch label we audited, gallbladder disease is a warning while hepatic impairment or disease is a contraindication, with separate caution for a history of cholestatic jaundice. Having no gallbladder does not prove the liver is healthy.

Why didn't my clinician mention gallbladder risk?

Gallbladder risk is one item in a much larger HRT benefit-risk decision, and it often changes the route discussion more than the basic possibility of treatment. It also sits between menopause care, primary care, gastroenterology, and surgery. Raise it directly using your imaging, surgical history, medication list, and the questions above.

---

The bottom line

A gallbladder history changes the questions, not automatically the possibility.

Oral estrogen has the clearest causal risk signal: roughly one extra gallbladder event per 323 women treated for a year with oral estrogen alone in WHI, and one per 500 with the oral combined regimen. Transdermal estrogen was associated with lower risk in two large prospective cohorts, but no randomized route trial proved it and the risk did not reach zero. Low-dose vaginal estrogen is a separate, much lower-systemic-exposure conversation when symptoms are local.

Active pain, inflammation, obstruction, jaundice, pancreatitis, or active liver disease belongs with in-person care before an online HRT decision.

And the warning on the leaflet? The same sentence appeared across all eight U.S. records we audited. Now you know what it is telling you — and what it is not.

Still not sure which HRT program is right for you? Take about 90 seconds to find your HRT path.

---

The HRT Index is an independent decision resource for online menopause and HRT care. This page is editorial research, not medical advice, and has not been medically reviewed by a clinician. FDA-approved and compounded options are labeled separately; compounded products are never presented as equivalent to, safer than, or more natural than FDA-approved medication. Last verified August 2026.